Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease

Parkinsonism and Related Disorders

Volumn 19, Issue 2, 2013, Pages 186-191

  Barrett, M J ^a   Hagenah, J ^b   Dhawan, V ^c   Peng, S ^c   Stanley, K ^a   Raymond, D ^a   Deik, A ^a   Gross, S J ^d,e   Schreiber Agus, N ^e   Mirelman, A ^f,g   Marder, K ^h   Ozelius, L J ⁱ   Eidelberg, D ^c   Bressman, S B ^a,d   Saunders Pullman, R ^a,d  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b UNIVERSITY OF LÜBECK   (Germany)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e JACOBI MEDICAL CENTER   (United States)

^f TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^g BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^h NewYork Presbyterian Hospital   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Diffuse Lewy body disease; Gaucher disease; GBA; Glucocerebrosidase; LRRK2; Parkinson disease; Parkinsonism; PET; Transcranial sonography

Indexed keywords

GLUCOSYLCERAMIDASE; GLYCINE; LEUCINE RICH REPEAT KINASE 2; SERINE;

ADULT; AGED; ARTICLE; BRAIN RADIOGRAPHY; BRAIN REGION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; FEMALE; FUNCTIONAL NEUROIMAGING; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GLUCOSYLCERAMIDASE GENE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IDIOPATHIC DISEASE; LEUCINE RICH REPEAT KINASE 2 GENE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONSET AGE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84873731061     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.09.007     Document Type: Article

References (40)

1. Bembi B., Zambito Marsala S., Sidransky E., Ciana G., Carrozzi M., Zorzon M., et al. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 2003, 61:99-101.
2. Goker-Alpan O., Schiffmann R., LaMarca M.E., Nussbaum R.L., McInerney-Leo A., Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet 2004, 41:937-940.
3. Tayebi N., Callahan M., Madike V., Stubblefield B.K., Orvisky E., Krasnewich D., et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001, 73:313-321.
4. Mitsui J., Mizuta I., Toyoda A., Ashkida R., Takahashi Y., Goto J., et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 2009, 66:571-576.
5. Ziegler S.G., Eblan M.J., Gutti U., Hruska K.S., Stubblefield B.K., Goker-Alpan O., et al. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 2007, 91:195-200.
6. Bras J., Paisan-Ruiz C., Guerreiro R., Ribeiro M.H., Morgandinho A., Januario C., et al. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging 2009, 30:1515-1517.
7. Kalinderi K., Bostantjopoulou S., Paisan-Ruiz C., Katsarou Z., Hardy J., Fidani L. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett 2009, 452:87-89.
8. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009, 361:1651-1661.
9. Gan-Or Z., Bar-Shira A., Mirelman A., Gurevich T., Kedmi M., Giladi N., et al. LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics 2010, 11:121-125.
10. Neumann J., Bras J., Deas E., O'Sullivan S.S., Parkkinen L., Lachmann R.H., et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009, 132:1783-1794.
11. Nichols W.C., Pankratz N., Marek D.K., Pauciulo M.W., Elsaesser V.E., Halter C.A., et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009, 72:310-316.
12. Berg D., Siefker C., Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001, 248:684-689.
13. Berg D., Godau J., Riederer P., Gerlach M., Arzberger T. Microglia activation is related to substantia nigra echogenicity. J Neural Transm 2010, 117:1287-1292.
14. Zecca L., Berg D., Arzberger T., Ruprecht P., Rausch W.D., Musicco M., et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 2005, 20:1278-1285.
15. Bruggemann N., Hagenah J., Reetz K., Schmidt A., Kasten M., Buchmann I., et al. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol 2010, 67:1357-1363.
16. Hagenah J.M., Becker B., Bruggemann N., Djarmati A., Lohmann K., Sprenger A., et al. Transcranial sonography findings in a large family with homozygous and heterozygous PINK1 mutations. J Neurol Neurosurg Psychiatr 2008, 79:1071-1074.
17. Hagenah J.M., Konig I.R., Becker B., Hilker R., Kasten M., Hedrich K., et al. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol 2007, 254:1407-1413.
18. Brueggemann N., Odin P., Gruenewald A., Tadic V., Hagenah J., Seidel G., et al. Re: alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008, 71:1294. author reply 1294.
19. Bruggemann N., Hagenah J., Stanley K., Klein C., Wang C., Raymond D., et al. Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Mov Disord 2011, 26:885-888.
20. Saunders-Pullman R., Hagenah J., Dhawan V., Stanley K., Pastores G., Sathe S., et al. Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov Disord 2010, 25:1364-1372.
21. Brockmann K., Srulijes K., Hauser A.K., Schulte C., Csoti I., Gasser T., et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011, 77:276-280.
22. Kono S., Ouchi Y., Terada T., Ida H., Suzuki M., Miyajima H. Functional brain imaging in glucocerebrosidase mutation carriers with and without parkinsonism. Mov Disord 2010, 25:1823-1829.
23. Pankratz N., Nichols W.C., Uniacke S.K., Halter C., Rudolph A., Shults C., et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without Parkin mutations. Am J Hum Genet 2002, 71:124-135.
24. Ozelius L.J., Senthil G., Saunders-Pullman R., Ohmann E., Deligtisch A., Tagliati M., et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006, 354:424-425.
25. Hagenah J., Konig I.R., Sperner J., Wessel L., Seidel G., Condefer K., et al. Life-long increase of substantia nigra hyperechogenicity in transcranial sonography. Neuroimage 2010, 51:28-32.
26. 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995, 45:1995-2004.
27. Asanuma K., Ma Y., Huang C., Carbon-Correll M., Edwards C., Raymond D., et al. The metabolic pathology of dopa-responsive dystonia. Ann Neurol 2005, 57:596-600.
28. Asanuma K., Tang C., Ma Y., Dhawan V., Mattis P., Edwards C., et al. Network modulation in the treatment of Parkinson's disease. Brain 2006, 129:2667-2678.
29. Trost M., Su S., Su P., Yen R.F., Tseng H.M., Barnes A., et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage 2006, 31:301-307.
30. Dhawan V., Ma Y., Pillai V., Spetsieris P., Chaly T., Belakhlef A., et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med 2002, 43:1324-1330.
31. Eckert T., Feigin A., Lewis D.E., Dhawan V., Frucht S., Eidelberg D. Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging. Mov Disord 2007, 22:167-173.
32. Ishihara L., Warren L., Gibson R., Amouri R., Lesage S., Durr A., et al. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol 2006, 63:1250-1254.
33. Beutler E., Gelbart T., Scott C.R. Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 2005, 35:355-364.
34. Poulopoulos M., Levy O.A., Alcalay R.N. The neuropathology of genetic Parkinson's disease. Mov Disord 2012, 27:831-842.
35. Clark L.N., Kartsaklis L.A., Wolf Gilbert R., Dorado B., Ross B.M., Kisselev S., et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009, 66:578-583.
36. Goker-Alpan O., Giasson B.I., Eblan M.J., Nguyen J., Hurtig H.I., Lee V.M., et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006, 67:908-910.
37. Westbroek W., Gustafson A.M., Sidransky E. Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med 2011, 17:485-493.
38. Walter U., Klein C., Hilker R., Benecke R., Pramstaller P.P., Dressler D. Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 2004, 19:1445-1449.
39. Gan-Or Z., Giladi N., Rozovski U., Shifrin C., Rosner S., Gurevich T., et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008, 70:2277-2283.
40. Horowitz M., Pasmanik-Chor M., Borochowitz Z., Falik-Zaccai T., Heldmann K., Carmi R., et al. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum Mutat 1998, 12:240-244.